Induced Pluripotent Stem Cell (IPS Cell) Market Trends, Size, Growth & Forecast 2028

Research Report

DataM Intelligence

The global induced pluripotent stem cell (IPS cell) market is expected to grow at a CAGR during the forecasting period (2021-2028).

The global induced pluripotent stem cell (IPS cell) market is expected to grow at a CAGR during the forecasting period (2021-2028).”

— DataM Intelligence


Market Overview
Induced pluripotent stem cells (iPS mobile), immature cell generated from a grownup (mature) mobile and has regained the capability to differentiate into any cell in the frame. IPSCs can be used to discover the reasons for disorder onset and development, create and take a look at new capsules and healing procedures, and doubtlessly treat formerly incurable diseases.

View full report:

Market Dynamics
The brought about pluripotent stem mobile (IPS cell) market increase is pushed by means of the growing healing advancements with iPS Cell, growing mergers and acquisitions of companies to enlarge their portfolio in iPSCs, Increasing studies sports are the predominant using factors of the marketplace.
A strong pipeline of iPSC is expected to drive the growth of the global induced pluripotent stem cell (IPS cell) market during the forecasting period.

The occurrence of persistent sicknesses internationally is riding many companies in the marketplace to increase novel caused pluripotent stem cell cures. Several tablets are inside the past due ranges of scientific trials and are anticipated to receive advertising and marketing approvals over the forecast length. For instance, I Peace Inc. And Avery Therapeutics is taking part to enhance an iPSC-derived cellular therapy for heart failure. I Peace is producing the GMP-grade iPSCs, whilst Avery Therapeutics is using them to manufacture its MyCardia. I Peace can mass manufacturing scientific-grade iPSC traces concurrently in an unmarried room using a miniaturized plate and robotic technology. Its facility is ready with the absolutely closed automated iPSC manufacturing system that meets the safety standards of the U.S. FDA and Japanese PMDA.

Hopstem Biotechnology is one of all China’s first iPSC cellular therapy agencies and a marketplace chief in iPSC-derived clinical-grade cellular merchandise. In June 2021, it partnered with Neurophth Biotechnology to co-expand an iPSC-derived cell therapy to treat ocular illnesses. Hopstem has a proprietary neural differentiation platform, a patented iPSC reprogramming approach, and GMP manufactory and best structures.

Some major disadvantages of iPSC are likely to hamper the market growth
The primary trouble is the use of retroviruses to generate iPSCs as they may be associated with most cancers, and mainly, retroviruses can insert their DNA anywhere within the genome and in the end cause most cancers-causing gene expression.
Moreover, in sure non-dividing mobile kinds (consisting of PBMCs or aged pores and skin fibroblasts), the reprogramming charge of somatic cells to iPSCs may be very low (less than 0.02 %). Thus, there’s additionally a want to evaluate the fine and variability of the reprogramming procedure.

Segment Analysis
By Type
• Human iPSCs
• Mouse iPSCs
By Application
• Drug Development and Discovery
• Academic Research
• Toxicity Screening
• Regenerative Medicine
• Others

Download free sample:

Geographical Analysis
North America region holds the largest market share of the global induced pluripotent stem cell (iPS Cell) market
North America holds the most important market in the global precipitated pluripotent stem mobile (iPS Cell) market. Currently, the U.S. Is the largest goal market for pluripotent stem cell (PSC) technology, with extra than 2,800 patent households filed? These bills for extra than 50% of the total patent households filed from 2006 to the present and enormous market gamers mounted in this region. Increasing investments in research & development for product innovations and a fine outlook toward business cattle are predicted to reinforce the local marketplace percentage. It is extensively followed as a lean meat substitute in North American international locations, particularly within the U.S. For example, Semma Therapeutics, which Vertex Pharmaceuticals obtained for $950 million in past-due 2019, is developing a remedy for Type 1 diabetes. This treatment includes cells derived from iPSCs that behave like pancreatic cells.

Competitive Landscape
The global induced pluripotent stem cell (IPS cell) market is highly competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include Axol Bioscience Ltd, Cynata Therapeutics Limited, Evotec SE, FUJIFILM Cellular Dynamics, Inc, Ncardia, Pluricell Biotech, REPROCELL USA, Inc, Sumitomo Dainippon Pharma Co., Ltd, Takara Bio, Inc, Thermo Fisher Scientific, Inc, Shenzhen Haodi Huatuo Biotechnology Co., Ltd, Wuxi Yingnuui Biomedical Technology, Shanghai Haoran Biotechnology Co., Ltd, ScienCell Research Laboratories, Inc, Beijing Lebo Biotechnology Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Cynata Therapeutics manufactures iPSC – derived MSCs using its proprietary Cymerus™ technology. In partnership with FUJIFILM Corporation, it is clinically testing these cells for the treatment of graft-versus-host disease (GvHD). It is also conducting trials for the treatment of critical limb ischemia (CLI), osteoarthritis (OA), and respiratory failure/distress, including ARDS.

Related Topic’s
Cancer Stem Cells Market, Stem Cell Therapy for Diabetes and Related Conditions Market, Animal Stem Cell Therapy Market

Sai Kiran
DataM Intelligence 4Market Research LLP
+1 877 441 4866
Visit us on social media:

Leave a Reply

Your email address will not be published.